Tumor Targeting of a STING Agonist by Means of an ADC Induces Anti-Tumor Immune Responses & Immunological Memory

Time: 4:40 pm
day: Day One


  • Mersana has developed the Immunosynthen platform to enable tumor-targeted delivery of a STING agonist by means of an ADC
  • Demonstrating how targeted STING-agonist ADCs induce potent anti-tumor immune responses and immunological memory
  • Understanding how targeted STING-agonist ADCs cause significantly more anti-tumor activity and dramatically less induction of systemic cytokines than intravenously administered free STING agonist